Trimovax

Description

TRIMOVAX  is a lyophilized  live attenuated vaccine containing Measles virus strain (cultivated on primary culture of chicken embryo cells), Mumps virus strain (cultivated in embryonated hen eggs) and Rubella virus strain (cultivated on human diploid cells) . Trimovax is indicated for combined prevention of measles, mumps and rubella, from 12 months of age in children of both sexes. For children in a collective environment (day care center), this limit is reduced to 9 months. This vaccine is recommended in children only.

Immunization guideline:

The first injection is administered from 12 months of age. A second injection is recommended between 3 and 6 years of age. 0.5 ml is the dose size. Subcutaneous or intramuscular route of administration should be followed.

For latest IAP updates see revised immunization schedule.

Additional information

vaccine-type

Measles, Mumps and Rubella

manufacturer

Aventis Pasteur, Sanofi Pasteur

country-of-manufacture

France, India

pharmaceutical-form

Lyophilized

package-size

1 Dose

route-of-administration

Intramuscular, Subcutaneous

preservative

None

Contraindications

Congenital or acquired immuno depressions (including infections by the human immunodeficiency virus), allergy to egg proteins (anaphylactic reaction after eating eggs), recent injection of immunoglobulins, pregnancy.